Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Precision BioSciences, Inc. (DTIL)

0.7536   0.052 (7.35%) 03-31 16:00
Open: 0.718 Pre. Close: 0.702
High: 0.76 Low: 0.7005
Volume: 708,860 Market Cap: 84(M)

Technical analysis

as of: 2023-03-31 4:18:09 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.17     One year: 1.4
Support: Support1: 0.68    Support2: 0.56
Resistance: Resistance1: 1    Resistance2: 1.2
Pivot: 0.8
Moving Average: MA(5): 0.74     MA(20): 0.86
MA(100): 1.16     MA(250): 1.46
MACD: MACD(12,26): -0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 14.4     %D(3): 13.7
RSI: RSI(14): 35.6
52-week: High: 3.08  Low: 0.68
Average Vol(K): 3-Month: 635 (K)  10-Days: 935 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DTIL ] has closed above bottom band by 31.9%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.78 - 0.79 0.79 - 0.79
Low: 0.69 - 0.7 0.7 - 0.7
Close: 0.7 - 0.7 0.7 - 0.71

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Headline News

Mon, 27 Mar 2023
Precision BioSciences to Participate in Upcoming Guggenheim ... - Business Wire

Sun, 26 Mar 2023
European Commission Grants Orphan Designation for iECURE's ... - Manchestertimes

Tue, 14 Mar 2023
Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way? - Simply Wall St

Thu, 09 Mar 2023
Precision BioSciences: Q4 Earnings Snapshot - The Herald Review

Thu, 09 Mar 2023
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 ... - Business Wire

Sun, 05 Mar 2023
Precision BioSciences (DTIL) to Release Earnings on Thursday - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 111 (M)
Shares Float 79 (M)
% Held by Insiders 17 (%)
% Held by Institutions 51 (%)
Shares Short 779 (K)
Shares Short P.Month 754 (K)

Stock Financials

EPS -1.25
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.55
Profit Margin (%) 0
Operating Margin (%) -399.9
Return on Assets (ttm) -27.9
Return on Equity (ttm) -147.3
Qtrly Rev. Growth 67.1
Gross Profit (p.s.) 0.22
Sales Per Share 0.22
EBITDA (p.s.) -0.84
Qtrly Earnings Growth 0
Operating Cash Flow -46 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -0.61
PEG Ratio 0
Price to Book value 1.37
Price to Sales 3.34
Price to Cash Flow -1.84

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.